In cerebral malaria, pathological changes can be found in the brain of infected people and in the brain of Plasmodium berghei-infected mice. The pathogenesis of cerebral malaria in mice is believed to be due to an immunopathological reaction giving rise to an excessive production of cytokines such as interferon y (IFN-'y) and tumor necrosis factor (TNF) . We find that low doses of interleukin 1 (Ilsl) protect mice against cerebral malaria ; IIr1 also inhibits parasitemia . The IIrl effect on parasitemia was not observed in nude mice and was at least partly reversed in mice treated with 11,1 in combination with antibody to IFN-y, indicating the involvement of T cells. Mice protected against development of cerebral malaria by IIr1 treatment developed the syndrome when TNF was given as observed in control infected mice or infected mice treated with inactivated ID1.
C erebral malaria is an important cause ofdeath in people infected with the human malaria parasite Plasmodium falciparum (1) . In a proportion of patients that die from cerebral malaria, inflammatory cells, loss of endothelial wall integrity, and hemorrhages are found in the brain at autopsy (2, 3). The pathogenesis ofhuman cerebral malaria, including that of the hemorrhages, is largely unexplained .
Similar findings are obtained in a murine malaria model after infection with P. berghei (4, 5) . Infection with this rodent malaria parasite can lead to the development of hemorrhages in the brains ofhamsters (6) , young rats (unpublished observations), and mice (4, 5, 7) . In P. berghei-infected mice, the development ofthe hemorrhages coincides with a sudden and irreversible decrease of the body temperature followed by rapid death (5) . There are indications that a T cell-dependent immunopathological reaction and excessive production ofcytokines, particularly IFN-y and TNF-a, play an important role in the pathogenesis of the brain hemorrhages in infected mice (5, 8) . Detrimental and even lethal effects of cytokines, such as TNF, have also been described in Gramnegative bacterial infections and endotoxemias (9) . There are, however, beneficial effects ofcytokines too. The cytokine 1171, administered in a low dose to mice, appears to protect mice from lethal infections due to bacteria such asPseudomonas aeruginosa, Klebsiella pneumoniag Listeria monocytogenes, and fungi such as Candida albicans (10) (11) (12) (13) (14) . Although the mechanism of protection has not yet been elucidated, it is an important question whether similar protection can be obtained against a parasitic disease such as lethal cerebral malaria . Therefore, and because of the strong functional relationship between TNF and ID1 (15), the effect of low dosages of human rII, 1a and r1L10 was investigated in lethal P. berghei infection in C57B1/6J mice.
Low-dose IIrl treatment inhibited parasite proliferation in a dose-dependent way, but only in intact mice, not in T cell-deficient nude mice. Independent of this effect on parasite proliferation, IIrl treatment prevented development of cerebral malaria.
Excessive TNF release is assumed to be responsible for most of the pathology associated with malaria (16) , and exogenous TNF given during infection can accelerate the development of the cerebral syndrome. IIr1 treatment, however, did not protect against this TNF-accelerated development of cerebral malaria in P. berghei-infected mice.
Materials and Methods
Mice. C57B1/6J mice were obtained from a local colony and housed under specific pathogen-free conditions with food (Hope Farms, Woerden, The Netherlands) and water ad libitum .
Parasite. P. berghei K173 was maintained by weekly transfer of parasitized erythrocytes (PE) from infected to naive mice. Experimental mice were infected with 1,000 PE intraperitoneally.
Parasitemia . Thin blood films were made from tail blood and stained with May-Grunwald and Giemsa's solutions .
Body Temperature. To measure body temperature, the probe of a digital thermometer (Technoterm ; Thermotex, The Hague, The Netherlands) was inserted in the rectum and read after 18 s.
Light and electron microscopy ofbrain tissue using routine histological procedures was carried out to detect the presence ofhemorrhages.
Interkukin 1 . Human MIAs was obtained from Dr. P Lomedico (Hoffmann-La Roche, Inc., Nutley, NJ) . Human rILrls was obtained from Dr. Alan Shaw (Glaxo, Geneva) .
Recombinant TNF-a was obtained fromDr. G. R. Adolf, Ernst Boehringer Institute, Vienna, Austria.
Anti-IFN-y Antibody.
mAb (DB-9) against mouse IFN-y was obtained from Dr. P.H. van der Meide (TN .O., Rijswijk, The Netherlands) .
Results and Discussion
Various IIA treatments were given to infected mice. When 80 ng of IIrla was given intraperitoneally for six consecutive days, starting on the day of infection, 78% of the mice were protected against cerebral malaria and experienced only a limited and transient change in body temperature ( Fig. 1  A) , whereas all mice that received heat-inactivated IDlot (100°C for 20 min) developed lethal cerebral malaria ( Fig.  1 A and 2 ). In addition, a remarkable delay of the development of the parasitemia was observed in mice treated with ID1( Fig . 1 B) . Although at day 12 parasitemia in IM-treated micebecame as high as in control mice at day 7 (control mice were treated with inactivated IIA), no dramatic decrease in body temperature and no cerebral hemorrhages occurred in the IIrl-treated group. Increasing daily dosages up to 320 ng IIr1 showed a further delay in the development of the parasitemia and again prevented development of cerebral malaria (Fig. 3) . It was found that a single intraperitoneal injection of 80 ng IIrla given 3 d after an intravenous infection with 1,000 parasites prevented death from cerebral bleedings in 50% (n = 10) of the animals. In addition, in all mice treated with IIrl on day 3 of infection, the course of the parasitemia was the same and independent ofdevelopment ofcerebral malaria. This makes it unlikely that protection against cerebral malaria by IIA treatment is due to its effect on parasitemia . IIA given as a single injection at day 0 (n = 5) or day 5 (n = 5) did not have an effect on parasitemia and did not prevent cerebral malaria . Perhaps a more important observation was that IIA given shortly before the development of the cerebral syndrome, i.e., on day 8 (n = 10), also did not affect the development o£ the syndrome. Comparable experiments using a 6-d treatment with 11,10 again showed protection against cerebral malaria and inhibition of parasitemia. Furthermore, implantation of osmotic pumps containing IIr1a 2 d before infection (calculated dose, 80 ng IIA/24 h; pumps active for 20 d) did have a similar effect on parasitemia and protected against the development of cerebral malaria, as did the 6-d treatment where IIrl was injected daily (n = 5). Inhibition of the proliferation of the parasite and protection against cerebral malaria were seen as the main effects from the various IIA treatments .
Based on these observations, a series of experiments was performed in order to determine a possible mechanism of action of 11,1. First, it is known that parasite proliferation is strongly dependent on erythropoietic activity, probably related to the parasite's preference for reticulocytes (17) , and IIA can suppress erythropoietin activity in vitro (18) , though its effect in vivo is less clear (18 or not ILA treatment suppresses erythropoiesis, thereby limiting parasitemia . Erythropoiesis was enhanced by letting 12 drops of blood from the retro-orbital plexus through a hematocrit capillary 1 d before IM treatment . 3 d after bleeding increased, reticulocyte counts were obtained (untreated controls: 1.2 ± 0.3% ; n = 5), but no difference was found between mice treated with IIr1 (5 .3 ± 2.1% ; n = 6) or inactivated IIA (5.3 ± 3.3%; n = 3). 6 d after bleeding, reticulocyte counts had returned to normal values . Second, since mouse studies have shown that T lymphocytes play an essential role in the immunopathology of malaria (5, 10), we investigated whether IIr1 could influence parasitemia in C57B1/6J nude mice (no cerebral malaria in T cell-deficient mice) Parasitemia was not influenced by IIr1 in these T cell-deficient animals (Fig. 4) . Thus, a direct effect on parasite proliferation is highly unlikely since IL1 is not effective against parasitemia in nude mice. Apparently, T lymphocytes or products of these cells are involved in this process, either by specific or nonspecific immunological effects on the parasite. The fact that the action of IM on the proliferation ofthe parasite is observed early during infection would be in favor of a nonspecific effect on the parasite, e.g., via sitemia in ILl-treated mice was 3.3 ± 3.2% (n = 3), and in mice treated with ILI and antibody to IFN-y, 7.3 ± 0.9% (n = 3) (p > 0.06); parasitemia in untreated mice was still higher (15 .7 ± 4.1%; n = 3). ILI protection against the development of cerebral malaria, however, was not reversed when antibody to IFN-y was added to the treatment . Treatment ofinfected mice with antibody against IFN-y without ILI had no effect on parasitemia (results not shown) . These data support the hypothesis that IL1-dependent suppression of parasitemia is at least partly mediated by an ILl-induced release of IFN-y from T cells . Specific immunological effects induced by ILI are not ruled out ; ILI can lead to enhanced production ofantibodies (20) , which can contribute to the prevention of the cerebral syndrome. Timely treatment with IgG from malaria-immune mice prevents severe hypothermia as well as the development of hemorrhages under conditions, where there is no effect on the course of the parasitemia, indicating that specific antibodies can protect against cerebral malaria (5) .
According to our c(ata protection against cerebral malaria and delayed parasitemia are not linked. This is in agreement with experiments in lethal Gram negative infection; in these studies survival was not due to increased microbicidal mechanisms (9, 10) . A hypothesis that came from those studies was that pretreatment with ILI interfered with the lethal effects of cytokines such as TNF (10) e.g., by modulating the receptors for this latter cytokine or by another mechanism of desensitization (21) . A similar mechanism of protection could be operational here. The work of Grau et al. (7) and Clark (22) suggests that TNF plays a pivotal role in the development of lethal malaria . Therefore it was investigated whether ILI would protect against the accelerated development of cerebral malaria ofP. berghei-infected mice by injection of exogenous TNF . Mice were infected with 1000 parasites and were treated for five days with ILI or inactivated ILI . On day 5 or later these mice were injected with 15 icg rec. human TNF. Within a few hours after injection of TNF, both ILI treated mice as well as control mice became hypothermic and died with cerebral hemorrhages. Uninfected mice injected with the same dose of TNF did not exhibit a decrease in body temperature and did not die. These results argue against the possibility that protection against cerebral malaria induced by ILI is due to a decreased sensitivity to TNF.
